Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Burning Rock Biotech (BNR) Non-Current Debt (2019 - 2025)

Burning Rock Biotech has reported Non-Current Debt over the past 3 years, most recently at $239687.4 for Q4 2025.

For Q4 2025, Non-Current Debt changed N/A year-over-year to $239687.4; the TTM value through Dec 2025 reached $239687.4, changed N/A, while the annual FY2025 figure was $243000.0, N/A changed from the prior year.
Non-Current Debt for Q4 2025 was $239687.4 at Burning Rock Biotech, down from $253000.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $253000.0 in Q3 2025 and troughed at $239687.4 in Q4 2025.